Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

Somerset facility State-of-the art facility for clinical and commercial manufacturing of oral dosage forms. Ghent, Belgium, ...

Ardena inks agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey: Ghent, Belgium Tuesday, October 15, 2024, 16:00 Hrs [IST] Ardena, a specialist pha ...

The FDA-approved Somerset facility employs approximately 200 skilled scientists and technicians and is a Center of Excellence for advanced delivery of oral dosage forms, complementing Ardena's ...

Catalent (CTLT) sells Somerset, NJ facility to Ardena. Corporate headquarters to shift to new location post-transition.

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...

Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said. ** Private equity ...

Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday.

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...

Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in ...

Jersey Township and the city of New Albany have collaborated to create a Cooperative Economic Development Agreement to ...